CBT Group Treatment for Women With Dyspareunia

April 19, 2022 updated by: Örebro University, Sweden

A Cognitive Behavioral Group Program-plus for Women With Dyspareunia: A Randomized Waiting List Controlled Multi-center Trial of Efficacy

The current study will employ a group CBT treatment program of 10 group sessions and 3 individual couple sessions targeting the thoughts, emotions, behaviors and couple interactions associated with the experience of dyspareunia. Women with superficial dyspareunia and their partners will be randomized to the CBT group program-plus or a waiting list control period at one treatment location in Sweden and two treatment locations in the Netherlands. The waiting-list control period will be comparable to the treatment duration of six months.

It is hypothesized that the group program-plus is more effective in improving pain during intercourse in women with superficial dyspareunia compared to women on a waiting-list control period.

Study Overview

Detailed Description

Rationale:

Superficial dyspareunia, a frequent form of chronic genital pain, is associated with decreased sexual function for afflicted women, as well as impoverished sexual satisfaction for women and their partners. While recent research has showed that cognitive-behavioral therapy (CBT) interventions have effects in regards to reducing pain, enhancing sexual function and improving relational aspects, randomized controlled trials are still sparse. Despite recommendations in the literature to include the partner in the CBT treatment targeted at improving pain and sexuality outcomes, there are no published randomized CBT controlled trials incorporating the partner in the treatment.

Primary objective: To evaluate whether the group program-plus improves pain during intercourse in women with superficial dyspareunia compared to women in a waiting-list control condition.

Secondary Objective(s): are to evaluate a) women (and partners) sexuality (sexual function, distress & satisfaction), b) women's psychological adjustment (negative and positive penetration beliefs, pain/penetration coping behavior); c) relationship factors (partner responses and relationship satisfaction), and whether an improvement in pain during intercourse is moderated by pre-treatment patient characteristics, such as age, sexual functioning, relationship satisfaction, abuse history, and mediated by a) reduction of negative penetration beliefs, avoidance behavior and/or improvement in positive penetration beliefs and sexual function (i.e. sexual arousal).

Study design:

Eligible women and their partners in one of the participating centers (n=3, in two countries) will be randomized to either the CBT group program-plus or waiting-list control group (WLC), using a block randomization design stratified for each center. The waiting-list period of 6 months is comparable to the period from the start of the active treatment until the post-treatment measurement. After the WLC, the patients from the WLC will receive the active treatment. Data of these participants will be included in the repeated measures analyses to test the temporal stability of treatment gains. Within-subjects repeated measures comparisons will be conducted for data of participants and their partners at pre-treatment, post-treatment, follow-up at 3 months and 6 months following treatment termination. In addition, participants complete monthly questionnaires at home during the first 6 months. Participants in the active treatment group will also complete weekly measures. These extra measurement are necessary for the mediation analyses. The total study duration (including follow-up) for the participants and their partners is 12-18 months.

Intervention:

The CBT group program-plus consists of 3 1-hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists will conduct the couple and group sessions.

Study Type

Interventional

Enrollment (Anticipated)

160

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Leiden, Netherlands, 2300
        • Not yet recruiting
        • Leiden University Medical Center, Department of Gynecology
        • Contact:
      • Maastricht, Netherlands, 6202
        • Not yet recruiting
        • Maastricht Universiy Medical Center (MUMC)
        • Contact:
      • Örebro, Sweden, 70182
        • Recruiting
        • Center for Health and Medical Psychology (CHAMP) Örebro University
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 43 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • woman
  • 18-45 years old
  • in a heterosexual relationship for at least 3 months
  • diagnosis of superficial dyspareunia (in accordance to DSM5) with no apparent ongoing physical cause to the condition (i.e. ongoing infections).
  • past experience of a successful intercourse
  • attempted intercourse during the last year

Exclusion Criteria:

  • reporting to never have had full intercourse at any time in life
  • partner not willing to participate in the study
  • major affective disorder, psychotic disorder, substance-related disorder or post traumatic-stress disorder related to the genitals (e.g., as a sequel to sexual abuse) according to DSM-5 criteria
  • being pregnant
  • gone through child delivery during the last year
  • not speaking Dutch or Swedish well enough to participate in assessment and treatment
  • receiving concurrent psychological therapy or physiotherapy for superficial dyspareunia during CBT or WLC period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: CBT group treatment
CBT group treatment-plus involving partners: 10 group sessions and 3 couple sessions
The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
Other: Waiting list
Six months waiting-list control condition.
The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
Waiting-list control condition during length of active treatment (6 months).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean level of pain during penile/vaginal intercourse (PI)
Time Frame: 6 months; 9 months; 12 months
Pain intensity is measured on a scale between 0-10
6 months; 9 months; 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Penetration behavior questionnaire (PBQ)
Time Frame: 6 months; 9 months; 12 months
The PBQ has seven questions inquiring about the woman's experience during the last month with the following aspects of vaginal penetration: full vaginal penetration with the penis of the partner, self-insertion in the vagina of one finger by the woman, self-insertion in the vagina of two fingers by the woman, insertion in the vagina of one finger by the partner, insertion in the vagina of two fingers by the partner, and self-insertion in the vagina of another object (such as a tampon or a dildo) by the woman and by the partner. Answering categories are as follows: (a) not attempted; (b) attempted, but unsuccessful; (c) attempted and sometimes successful; and (d) attempted and always successful. The total of the scale is calculated and ranges between 4-28.
6 months; 9 months; 12 months
Genital pain rating questionnaire (GPQ)
Time Frame: 6 months; 9 months; 12 months
Genital pain experienced by touch and penetration of the vagina will be assessed with the 7- item Genital Pain rating Questionnaire (GPQ). Response categories vary from 0 (not at all) to 10 (worst pain imaginable). The questionnaire consist of two sub-scales: the first sub-scale 'pain on touch and finger insertion'' consists of 6 items (pain by touch of the vulva by the patient herself, pain by touch of the vulva by the patient's partner, pain during insertion of one/two own finger(s) into the vagina, and pain during insertion of one/two finger(s) of the patient's partner) into the vagina. The range of the sub-scale is 0-60. The second sub-scale is 1 item related to pain during intercourse (0-10).
6 months; 9 months; 12 months
Female Sexual Function Index (FSFI)
Time Frame: 6 months; 9 months; 12 months
Female Sexual functioning will be assessed with the 19-item Female Sexual Function Index (FSFI). It covers six domains of sexual functioning: sexual desire, sexual arousal, lubrication, orgasm, sexual satisfaction, and sexual pain. The answers are given on a Likert scale ranging from 0 or 1 to 5, depending on item. For the current study, the total FSFI score will be used, excluding the three items on sexual pain, which gives an indication of the sexual functioning during the past four weeks. The total score ranges between 2-30 with higher scores indicating higher sexual function.
6 months; 9 months; 12 months
Female Sexual Distress scale (FSDS)
Time Frame: 6 months; 9 months; 12 months
Sexual related personal distress will be assessed with the 12-item Female Sexual Distress scale (FSDS). Questions are answered on a 0-4 Likert scale and the total score ranges from 0-48 with higher scores indicating higher sexual distress.
6 months; 9 months; 12 months
Global Measure of Sexual Satisfaction Scale (GMSEX)
Time Frame: 6 months; 9 months; 12 months
Sexual satisfaction will be assessed with the 5-item Global Measure of Sexual Satisfaction Scale (GMSEX). GMSEX consist of five 7-point dimensions of sexual satisfaction ranging from "Good" to "Bad", "Pleasant" to "Unpleasant", "Positive" to "Negative", "Satisfying" to "Unsatisfying", and "Valuable" to "Worthless". Total scores range from 5-35, with higher scores indicating greater sexual satisfaction.
6 months; 9 months; 12 months
Vaginal Penetration Cognition Questionnaire (VPCQ)
Time Frame: 6 months; 9 months; 12 months
Positive and negative cognitions and beliefs regarding vaginal penetration will be assessed with the 22-item Vaginal Penetration Cognition Questionnaire (VPCQ). The VPCQ is a 22-item self-report measure using positive and negative statements about vaginal penetration and is answered on a 7-point Likert scale. Possible answers range from "0 = not at all applicable" to "6 = very strongly applicable." The VPCQ consists of 5 subscales: Control Beliefs (4 items), Catastrophic and Pain Beliefs (5 items), Self-Image Beliefs (6 items), Positive Beliefs (5 items), and Genital Incompatibility Beliefs (2 items).
6 months; 9 months; 12 months
Painful Intercourse Self-Efficacy Scale (PISES)
Time Frame: 6 months; 9 months; 12 months
Pain self-efficacy beliefs will be assessed using the 20-item Painful Intercourse Self-Efficacy Scale (PISES), it consists of three sub-scales: self-efficacy for controlling pain during intercourse, for sexual function, and for other symptoms. Answers are given on a 10-point scale ranging from (10) very uncertain to (100) very certain.
6 months; 9 months; 12 months
CHAMP Sexual Pain Coping Scale (CSPCS)
Time Frame: 6 months; 9 months; 12 months
Avoidance and endurance coping behaviors during penetration will be assessed with the 12-item CHAMP Sexual Pain Coping Scale (CSPCS). This measure consists of three sub-scales: avoidance, endurance and alternative strategies. Respondents rate their agreement of each statement between 1 ("Never true") and 7 ("Always true"). Total scores range from 4-28 on each sub-scale.
6 months; 9 months; 12 months
Maudsley Marital Questionnaire (MMQ)
Time Frame: 6 months; 9 months; 12 months
Relationship satisfaction will be assessed with the 10 items of the marital dissatisfaction subscale of the Maudsley Marital Questionnaire MMQ. Possible range 0-80 with higher scores indicating greater dissatisfaction.
6 months; 9 months; 12 months
Approach and Avoidance Sexual Goals (AASG)
Time Frame: 6 months; 9 months; 12 months
To assess sexual motives and goals the 15-item Approach and Avoidance Sexual Goals (AASG) measure will be used. Participants can rate the importance of 9 approach and 6 interpersonal goals in influencing their decision to engage in sex on a 7 point scale.
6 months; 9 months; 12 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Health Questionnaire (PHQ-9)
Time Frame: 6 months; 9 months; 12 months
Symptoms of depression will be assessed with the 9 item Patient Health Questionnaire (PHQ-9). The answers are given on a scale between 0-3 and total scores ranges between 0-27 with higher scores indicative of higher symptoms of depression.
6 months; 9 months; 12 months
Generalized Anxiety Disorder-7 (GAD-7)
Time Frame: 6 months; 9 months; 12 months
Symptoms of anxiety will be assessed with the 7 item generalized anxiety disorder-7 (GAD-7). The answers are given on a scale between 0-3 and total scores ranges between 0-21 with higher scores indicative of higher symptoms of anxiety.
6 months; 9 months; 12 months
International Index of Erectile Dysfunction (IIEF)
Time Frame: 6 months; 9 months; 12 months
Male sexual function will be assessed with the 15 items of the International Index of Erectile Function (IIEF) which is a widely used, multi-dimensional self-report instrument for the evaluation of male sexual function. The answers are given on a Likert scale ranging from 0 or 1 to 5, depending on item. For the current study, the total IIEF score will be used, which gives an indication of the sexual functioning during the past four weeks. The total score ranges between 2-30 with higher scores indicating higher sexual function.
6 months; 9 months; 12 months
Male Sexual Distress Scale (MSDS)
Time Frame: 6 months; 9 months; 12 months
Sexual related personal distress will be assessed with the 12-item Female Sexual Distress scale (FSDS). Because the FSDS does not contain gender specific items, the measure has also successfully been administered to male participants. Questions are answered on a 0-4 Likert scale and the total score ranges from 0-48 with higher scores indicating higher sexual distress.
6 months; 9 months; 12 months
Perceived treatment improvement and satisfaction
Time Frame: 6 months; 9 months; 12 months
Self-reported improvement (scale of 0 (worse) to 5 (complete cure)) and treatment satisfaction (scale of 0 (completely dissatisfied) to 10 (completely satisfied)) are measured to assess the clinical significance of results.
6 months; 9 months; 12 months
EuroQual5 (EQ-5D)
Time Frame: 6 months; 9 months; 12 months
Is used to assess general function. The visual analogue scale (VAS) of the EQ-5D will be used as a quantitative measure of health as judged by the woman and her partner ranging between 0-100.
6 months; 9 months; 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ida K Flink, PhD, Örebro University, Sweden
  • Principal Investigator: Moniek M ter Kuile, PhD, Leiden University Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 29, 2017

Primary Completion (Anticipated)

December 31, 2023

Study Completion (Anticipated)

December 31, 2023

Study Registration Dates

First Submitted

December 1, 2017

First Submitted That Met QC Criteria

February 2, 2018

First Posted (Actual)

February 9, 2018

Study Record Updates

Last Update Posted (Actual)

April 20, 2022

Last Update Submitted That Met QC Criteria

April 19, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • CBT group program-plus

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyspareunia

Clinical Trials on CBT group treatment-plus

3
Subscribe